FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer By Ogkologos - September 23, 2026 121 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAddition study Source RELATED ARTICLESMORE FROM AUTHOR Adding Abiraterone to ADT and Docetaxel Improves Survival in Metastatic Prostate Cancer A glucometer for cancer: towards a scalable, universal residual disease measurement Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes MOST POPULAR Fostering Growth and Creativity Through Journaling August 11, 2021 Mom Is Warning Other Parents After Her Son Was Bit By... May 24, 2019 Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma December 10, 2025 How Therapy Helped Me Cope During Cancer: A Survivor’s Perspective October 24, 2023 Load more HOT NEWS Honoring our Labor New Mom Was Told a Lump in Her Breast Was “Built-Up... Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated... Teacher on Leave for Breast Cancer Treatment Forced to Pay for...
